J. Alfred Witjes spends much of his time researching Bladder cancer, Prostate cancer, Surgery, Magnetic resonance imaging and Cancer. Bladder cancer is a subfield of Internal medicine that J. Alfred Witjes investigates. The Prostate cancer study combines topics in areas such as Prostate, Mr imaging and Nuclear medicine.
His work carried out in the field of Surgery brings together such families of science as Meta-analysis, Cystectomy, Cystoscopy and Urology. Magnetic resonance imaging is a subfield of Radiology that J. Alfred Witjes explores. His Cancer study combines topics from a wide range of disciplines, such as Genome-wide association study and Gynecology.
His main research concerns Bladder cancer, Urology, Internal medicine, Prostate cancer and Surgery. His Bladder cancer research entails a greater understanding of Cancer. His Cancer research is multidisciplinary, relying on both Odds ratio and Gynecology.
In the subject of general Urology, his work in Urinary bladder is often linked to In patient, thereby combining diverse domains of study. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology, Oncology and Pathology. His research integrates issues of Biopsy, Magnetic resonance imaging, Radiology and Prostate in his study of Prostate cancer.
His primary areas of investigation include Bladder cancer, Urology, Internal medicine, Cystectomy and Cystoscopy. His Bladder cancer research focuses on Non muscle invasive in particular. J. Alfred Witjes combines subjects such as Cancer, Adverse effect, Hyperthermia, Toxicity and Mitomycin C with his study of Urology.
His Internal medicine research focuses on subjects like Oncology, which are linked to Biomarker and Progressive disease. He interconnects Carcinoma in situ, Guideline, Intensive care medicine, Perioperative and General surgery in the investigation of issues within Cystectomy. His studies deal with areas such as Biopsy, Prostate and Confidence interval as well as Prostate cancer.
J. Alfred Witjes focuses on Bladder cancer, Urology, Cystectomy, Internal medicine and Cystoscopy. His biological study spans a wide range of topics, including Chemotherapy, Cytology, Urine, Disease and Biomarker. Gold standard and Receiver operating characteristic is closely connected to Clinical trial in his research, which is encompassed under the umbrella topic of Urology.
His Cystectomy research integrates issues from Guideline, Perioperative, Randomized controlled trial and Evidence-based medicine. His work investigates the relationship between Internal medicine and topics such as Oncology that intersect with problems in Immunotherapy. His research investigates the connection between Cystoscopy and topics such as Confidence interval that intersect with issues in Patient summary and Intravesical chemotherapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.
Richard J. Sylvester;Adrian P.M. van der Meijden;Willem Oosterlinck;J. Alfred Witjes.
European Urology (2006)
Erratum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer (Nature Genetics (2009) 41 (991-995))
Xifeng Wu;Yuanqing Ye;Lambertus A. Kiemeney;Patrick Sulem.
Nature Genetics (2009)
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
J. Alfred Witjes;Thierry Lebret;Eva M. Compérat;Nigel C. Cowan.
European Urology (2017)
EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
J. Alfred Witjes;Eva Compérat;Nigel C. Cowan;Maria De Santis.
European Urology (2014)
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.
Julius Gudmundsson;Patrick Sulem;Andrei Manolescu;Laufey T Amundadottir.
Nature Genetics (2007)
DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer
Daphne Hessels;Jacqueline M.T. Klein Gunnewiek;Inge van Oort;Herbert F.M. Karthaus.
European Urology (2003)
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy.
Bas W.G. van Rhijn;Maximilian Burger;Yair Lotan;Eduardo Solsona.
European Urology (2009)
Many sequence variants affecting diversity of adult human height
Daniel F Gudbjartsson;G Bragi Walters;Gudmar Thorleifsson;Hreinn Stefansson.
Nature Genetics (2008)
Prostate Cancer: Multiparametric MR Imaging for Detection, Localization, and Staging
Caroline M A Hoeks;Jelle O Barentsz;Thomas Hambrock;Derya Yakar.
Radiology (2011)
An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer
Per-Uno Malmström;Richard J. Sylvester;David E. Crawford;Martin Friedrich.
European Urology (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Radboud University Nijmegen
Radboud University Nijmegen
Radboud University Nijmegen
University of Tübingen
Memorial Hospital of South Bend
deCODE Genetics (Iceland)
Radboud University Nijmegen
Radboud University Nijmegen
European Organisation for Research and Treatment of Cancer
The University of Texas MD Anderson Cancer Center
University of Miami
Technion – Israel Institute of Technology
Cornell University
University of Manchester
University of Regensburg
Energy Conversion Devices
University of Copenhagen
Inserm : Institut national de la santé et de la recherche médicale
Baylor College of Medicine
Federal University of Mato Grosso do Sul
Université Laval
Goddard Space Flight Center
Université Libre de Bruxelles
Memorial Sloan Kettering Cancer Center
University of Nairobi
Australian National University